Alevio Funding: How Much Did They Raise & Key Investors

How Much Did Alevio Raise?
Funding & Key Investors

Alevio has successfully secured a major strategic investment, marking a significant milestone in its corporate evolution. With a cumulative capital infusion reaching $420K, the firm continues to solidify its market position through a recent funding round totaling $270K. This influx of liquidity underscores investor confidence in the company's specialized approach to spinal health and its capacity to scale operations within the competitive medical device landscape.

The financial trajectory, characterized by successive debt financing rounds, reflects a deliberate strategy to bolster balance sheets while maintaining operational autonomy. By leveraging these resources, Alevio is well-positioned to accelerate its commercial reach and refine its clinical offerings in the sacroiliac joint treatment sector.

What is Alevio?

Alevio

Manufacturing

Medical Devices & Equipment

Alevio Spine operates at the intersection of orthopedic innovation and patient-centric care, focusing specifically on the development of minimally invasive surgical treatments for sacroiliac joint pain. The company's flagship offering, the SI-Cure Implant System, represents a sophisticated solution designed to address chronic low back pain through precise, physician-tailored interventions. By prioritizing both technological efficacy and patient education, Alevio has carved out a distinct niche in the spinal surgery market, providing healthcare providers with the tools necessary to improve patient outcomes in a high-demand therapeutic area.

How much funding has Alevio raised?

Alevio has raised a total of $420K across 2 funding rounds:

2020

Debt

$150K

2021

Debt

$270K

Debt (2020): $150K with participation from PPP

Debt (2021): $270K led by PPP

Key Investors in Alevio

PPP

Public-Private Partnership

Undisclosed Investors

What's next for Alevio?

Looking ahead, the strategic deployment of this capital will likely center on expanding the clinical footprint of the SI-Cure Implant System and enhancing the company's educational outreach programs. As Alevio navigates the complexities of the late-stage growth phase, the focus will shift toward optimizing supply chain efficiencies and broadening market penetration among orthopedic specialists. The firm's ability to maintain its momentum will depend on its continued commitment to clinical excellence and its capacity to navigate the evolving regulatory environment governing spinal implant technologies. This financial backing provides the necessary runway to solidify Alevio's status as a leader in sacroiliac joint fusion solutions.

See full Alevio company page

See More Financial Insights